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Interleukin (IL)-23 is a heterodimeric cytokine composed of a unique p19 subunit, and a 
common p40 subunit shared with IL-12. IL-12 is important for the development of T helper 
(Th)1 cells that are essential for host defense and tumor suppression. In contrast, IL-23 does 
not promote the development of interferon-
 
 
 
–producing Th1 cells, but is one of the 
essential factors required for the expansion of a pathogenic CD4
 
 
 
 T cell population, which 
is characterized by the production of IL-17, IL-17F, IL-6, and tumor necrosis factor. Gene 
expression analysis of IL-23–driven autoreactive T cells identified a unique expression 
pattern of proinflammatory cytokines and other novel factors, distinguishing them from 
IL-12–driven T cells. Using passive transfer studies, we confirm that these IL-23–dependent 
CD4
 
 
 
 T cells are highly pathogenic and essential for the establishment of organ-specific 
inflammation associated with central nervous system autoimmunity.
 
IL-23 plays a pivotal role in the establishment
and maintenance of organ-specific inflam-
matory autoimmune diseases. In particular,
we have demonstrated that IL-23–deficient
(IL-23p19
 
   
 
) mice are resistant to experi-
mental autoimmune encephalomyelitis (EAE),
collagen-induced arthritis (CIA; references 1, 2),
and IBD (unpublished data), highlighting an
important role of this cytokine in autoimmune
pathogenesis. Although IL-23 shares a common
p40 subunit with IL-12 (3), these cytokines
have divergent activities. IL-12 is an important
factor for the differentiation of naive T cells
into IFN-
 
 
 
–producing Th1 cells, is essential
for antimicrobial responses (4, 5), and serves as
a suppressor of human B cell tumors (6). IL-23–
deficient mice display normal immune re-
sponses to acute microbial infections such as
 
Toxoplasma gondii
 
. (7). However, IFN-
 
 
 
   
 
 (8),
IFN-
 
 
 
R
 
   
 
 (9), IL-12R
 
 
 
2
 
   
 
 (10), and IL-
12p35
 
   
 
 mice (11, 12), which all lack critical
components of the Th1–IFN-
 
 
 
 pathway, are
highly susceptible to inflammatory autoim-
mune diseases, questioning whether IFN-
 
 
 
–
producing T cells have an essential role in
autoimmune pathogenesis. In this paper, we
demonstrate that IL-23 promotes a T cell pop-
ulation characterized by the production of IL-17,
IL-17F, TNF, IL-6, and other additional novel
factors. Upon adoptive transfer to naive recipi-
ent mice, this IL-23–dependent T cell subset
invades the target organ and can promote the
development of organ-specific autoimmune
inflammation.
 
RESULTS
Differential cytokine expression of central 
nervous system (CNS)–infiltrating CD4
 
 
 
 T cells
 
To study the role of IL-23 in autoimmune in-
flammatory disease pathogenesis, we used a
CNS autoimmune model because the target
organ is normally free of activated macro-
phages and CD4
 
 
 
 T cells (13); therefore, we
can monitor the infiltration of inflammatory
cells into the CNS during disease develop-
ment. Just before disease onset, myelin-oligo-
dendrocyte glycoprotein peptide (MOG)
 
35-55
 
–
primed WT mice exhibited a large influx of
CNS-invading immune cells (Fig. 1 A). Sur-
prisingly, although IL-23–deficient mice (IL-
23p19
 
   
 
) were completely EAE resistant, com-
parable numbers of immune cells invaded the
CNS (Fig. 1 A). In vitro stimulation of the
CNS-invading CD4
 
 
 
 cells showed equivalent
number of MOG-specific, IFN-
 
 
 
–producing
cells in both the IL-23p19
 
   
 
 and WT mice
(Fig. 1 B), suggesting that IL-23 is not re-
quired for T cell migration across the blood–
brain barrier or for Th1 cell development. In
addition, the presence of Th1 cells capable of
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producing IFN-
 
 
 
 within the CNS of IL-23–deficient mice is
not sufficient to induce EAE. Intracellular cytokine analysis
also detected IL-6, IL-17, and TNF in the CNS-infiltrating
CD4
 
 
 
 T cells from WT mice. In contrast, CD4
 
 
 
 T cells iso-
lated from IL-23p19
 
   
 
 mice displayed reduced IL-6 and un-
detectable IL-17 production (Fig. 1 B). TNF production was
also markedly reduced in the IL-23p19
 
   
 
 cells, consistent
with a previous paper suggesting that IL-23 is required for
TNF production by CNS-infiltrating T cells (12). Ex vivo
analysis of draining LN (DLN) cells from immunized WT
and IL-23p19
 
   
 
 mice reflected the CNS data, with similar
IFN-
 
 
 
 levels, but no IL-17 production by the IL-23p19
 
   
 
cells (2, 14, 15). These results suggest that IL-23 is not re-
quired for Th1 development, but is essential for the develop-
ment of autoantigen-specific, IL-17–producing CD4
 
 
 
 T
cells.
 
IL-23 drives an IL-17–producing T cell population
 
To confirm our in vivo data, next we cultured antigen-
primed DLN cells in vitro with IL-23 to analyze cytokine
production and proinflammatory gene expression. DLN cells
isolated from SJL mice immunized with proteolipid protein
peptide (PLP)
 
139-151
 
 were cultured in the presence of PLP, plus
rIL-23, rIL-12, or medium alone. Immediately after ex vivo
isolation, CD4
 
 
 
 PLP-specific IFN-
 
 
 
–producing (Th1) cells
and IL-17–producing (Th
 
IL-17
 
) cells were identified in the iso-
lated DLN cells after PMA restimulation (Fig. 2 A). Adminis-
tration of rIL-23 promoted the expansion of Th
 
IL-17
 
 cells, and
reduced the growth of Th1 cells after 5 d of culture (Fig. 2, A
and B). In contrast, addition of rIL-12 promoted Th1 but re-
duced Th
 
IL-17
 
 growth (Fig. 2 A and B). These results are con-
sistent with papers suggesting that IL-23 is required for the de-
velopment and expansion of IL-17–producing CD4
 
 
 
 T cells
(2, 16, 17). Both Th
 
IL-17
 
 and Th1 cells also produced TNF
(Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20041257/DC1) and were characterized as CD4
 
 
 
CD62L
 
lo
 
 CD44
 
hi
 
, indicative of activated T cells; however, the
Th
 
IL-17
 
 cells displayed lower CD45RB expression (Fig. S1 B).
Th
 
IL-17
 
 CNS-infiltrating T cells isolated from myelin antigen-
immunized mice are also CD62L
 
lo
 
 CD44
 
hi
 
 CD45RB
 
lo
 
 (un-
published data). DLN cells taken from IL-12p40
 
   
 
 mice,
which lack both IL-12 and IL-23, could still be driven in cul-
ture with rIL-23 or rIL-12 to generate Th
 
IL-17
 
 or Th1 cells, re-
spectively (Fig. 2 C). This suggests that IL-12 and IL-23 are
not required during in vivo priming for subsequent in vitro
generation of IL-23 responsive Th
 
IL-17
 
 cells.
To address whether Th
 
IL-17
 
 cells can be generated in vitro
from naive T cells, without in vivo priming, we isolated
TCR-transgenic naive CD4
 
 
 
 T cells from DO11.10 Tg 
 
 
Figure 1. T cells and inflammatory macrophages enter the CNS of 
MOG-immunized IL-23p19    mice. (A) Phenotypic analysis of CNS-
infiltrating cells in the brains of WT and IL-23p19    mice at day 7 (before 
EAE onset) after immunization with MOG/CFA. (B) Intracellular cytokine 
staining of day 7 CNS-infiltrating cells from WT and IL-23p19    mice 
after 18 h of stimulation with 100  g/ml MOG peptide, all plots are gated 
on live CD4  T cells. Data are representative of five separate experiments.
Figure 2. IL-23 promotes the expansion of IL-17 producing CD4  
(ThIL-17) cells. (A) Intracellular IL-17 and IFN-  production by CD4  DLN 
cells isolated from PLP-immunized WT SJL mice, either immediately after 
ex vivo isolation, or cultured with PLP139-151 peptide plus either rIL-12, rIL-23, 
or no added cytokine for 5 d. All plots are gated on live CD4  T cells. 
(B) Mean percentage ( 1 SD of error) of CD4  T cells producing IFN-  or 
IL-17 in response to 5 d of culture with IL-12 or IL-23. *, Student’s unpaired 
t test, P   0.02, averaged from eight separate experiments. (C) Intracellular 
IL-17 and IFN-  production by CD4  DLN cells isolated from MOG-immunized 
p40    C57BL/6 either immediately after ex vivo isolation or cultured for 
5 d with rIL-12 or rIL-23. All intracellular staining samples were restimulated 
with PMA/ionomycin for 4 h before analysis. All plots are gated on live 
CD4  T cells and are representative of three independent experiments. 
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Rag
 
   
 
 mice, and stimulated them with anti-CD3/anti-
CD28 in the presence of rIL-12 or rIL-23. By day 7, the cul-
tured cells were all CD62L
 
lo
 
, indicative of an activated pheno-
type (Fig. 3 A). Upon restimulation with PMA/ionomycin, a
small number of these activated T cells produced IL-17 in the
IL-23–driven culture. These results suggest that a subpopula-
tion of naive T cells can respond to IL-23 upon in vitro acti-
vation. In contrast, IL-12–driven cells produced high levels of
IFN-
 
 
 
 and no IL-17 in vitro (Fig. 3 B). The naive T cells are
biased toward IFN-
 
 
 
 production after anti-CD3/anti-CD28
stimulation. In the absence of exogenous cytokines, a small
number of T cells producing IFN-
 
 
 
 (
 
 
 
5%) were present after
anti-CD3/anti-CD28 stimulation (Fig. 3 B). The same fre-
quency of IFN-
 
 
 
 producers were found in the IL-23 driven
cultures, suggesting that during primary in vitro stimulation,
IL-23 is unable to affect IFN-
 
 
 
 levels. As seen with SJL DLN
cultured cells, three to four rounds of in vitro IL-23 stimula-
tion lead to reduction of IFN-
 
 
 
 producers (unpublished data).
Next, we parked purified naive DO11.10 Tg 
 
 
 
 Rag
 
   
 
CD4
 
 
 
 T cells into BALB/c hosts. After OVA
 
323-339
 
/CFA
immunization, DLN cells were isolated 4 d later and ana-
lyzed immediately. A small subset of KJ1-26
 
 
 
 T cells were
capable of producing IL-17 and were characterized as CD62L
 
lo
 
and CD44
 
hi
 
 (Fig. 3, C and D). These results suggest that sub-
cutaneous OVA
 
323-339
 
/CFA priming, which induces IL-23
expression in the DLN (not depicted) and also induces IL-
17–producing T cells (Fig. 3 C). Both Th1 and Th
 
IL-17
 
 cells
were present in the KJ1-26
 
 
 
 OVA-primed DLN, indicating
that both Th1 and Th
 
IL-17
 
 cells can be generated from naive
T cells. However, it is likely that additional factors are re-
quired to enhance IL-23 responsiveness.
 
Gene expression pattern induced by IL-12 versus IL-23
 
Next, we compared the gene expression profile of rIL-23– or
rIL-12–stimulated PLP-specific CD4
 
 
 
 T cells by real-time
PCR to study the functional characteristics of these different
cell populations. Both IL-12– and IL-23–driven cells expressed
constitutive levels of IL-12R
 
 
 
1 (unpublished data). IL-12
drives high expression of IL-12R
 
 
 
2, but little IL-23R, consis-
tent with the ability of these cells to respond to IL-12 (Fig. 4
A). IFN-
 
 
 
 and granzyme G expression was also significantly
increased. Conversely, IL-23 drives high mRNA expression
of IL-23R, but little IL-12R
 
 
 
2, consistent with the ability of
these cells to respond to IL-23 (Fig. 4 A). IL-17, IL-17F, IL-6,
and TNF RNA levels were also significantly elevated; how-
ever, IFN-
 
 
 
 and granzyme G expression were dramatically re-
duced in the IL-23 driven cultures (Fig. 4 A). Integrin-
 
 
 
3,
which enhances cellular migration within the target organ
during inflammation (18), was also up-regulated in the IL-23–
driven cells. These results suggest that the IL-23–driven T cells
may play an important role in organ-specific inflammation, but
not immune surveillance, via the classical IL-12–depen-
dent IFN-
 
 
 
 pathway. Further analysis of 
 
 
 
200 lymphoid
and myeloid-specific genes by real-time PCR, comparing to-
tal (lymphoid and myeloid) DLN cells cultured with rIL-23 or
rIL-12 showed that 
 
 
 
80% of the genes displayed comparable
expression profiles (Fig. 4 B). Of the remaining genes showing
divergence, IL-12 elevated expression of many host defense
genes such as granzyme F, granzyme G, TRAIL, BLYS, IFN- ,
TRAIL R2, and FASL. However, IL-23 induced, in addition
to IL-17 and IL-17F, elevated expression of genes such as
CCL7, CCL17, CCL20, CCL22, CCR1, and GM-CSF. We
are currently characterizing the molecular basis of the cellular
responses to IL-12 versus IL-23 by microarray analysis. Pre-
liminary data identifies that IL-12 specifically induced 306
genes (greater than fivefold), comprised of many cytotoxicity
and host defense genes. In contrast, IL-23 specifically induced
162 genes (greater than fivefold), including numerous novel
expression sequence tags with unknown functions in addition
to a 34-fold increase of IL-17 (unpublished data). Together,
these results suggest that IL-12, not IL-23, drives development
of T cell–expressing host defense genes. The precise in vivo
Figure 3. IL-23 drives a small population of naive T cells to produce 
IL-17 after in vitro activation. (A) Surface expression of CD62L on naive 
splenic DO11.10   Rag    T cells, either analyzed immediately after isola-
tion (ex vivo) or on day 7 after in vitro anti-CD3/anti-CD28 stimulation 
plus IL-12 or IL-23. (B) Intracellular cytokine staining of CD4  DO11.10   
Rag    T cells on day 7 after in vitro anti-CD3/anti-CD28 stimulation plus 
IL-12 or IL-23. Cells were restimulated with PMA/ionomycin for 4 h before 
intracellular staining. (C) Naive DO11.10   Rag    T cells were parked in 
BALB/c recipients and OVA/CFA immunized. DLN cells were restimulated, 
PMA/ionomycin and intracellular stained for IL-17 and IFN-  or (D) surface 
stained for CD44 and CD62L. All plots are gated on CD4  KJ1-26  cells. 
Results are representative of two experiments.IL-23 DRIVES PATHOGENIC T CELLS | Langrish et al. 236
function of IL-23 is currently unclear. Its capacity to induce
IL-17 and other proinflammatory factors appears important
for neutrophil recruitment (17) and granuloma formation
(19). However, when dysregulated, it causes inflammatory
responses often associated with autoimmunity.
ThIL-17 cells are highly encephalogenic
To compare the capacity of Th1 versus ThIL-17 cells to induce
EAE pathology, we transferred IL-23– or IL-12–expanded
PLP-specific cells to naive recipient mice. To confirm that
both IL-23– and IL-12–cultured cells were viable in vivo
Figure 4. Gene expression analysis of IL-23 versus IL-12 driven T 
cells. (A) Quantitative analysis of mRNA expression levels of selected 
genes, comparing sorted CD4  DLN cells isolated from PLP-immunized 
mice, either not cultured (ex vivo) or cultured with rIL-23 or rIL-12 for 10 d. 
(B) Quantitative analysis of mRNA expression levels of  200 selected 
genes, comparing total DLN cells isolated from PLP-immunized mice, cul-
tured with either rIL-23 or rIL-12 for 10 d. All samples were activated with 
PMA/ionomycin for 4 h before RNA extraction and Taqman analysis. Results 
are normalized to a housekeeping gene, ubiquitin, and representative of 
two similar experiments.
Figure 5. IL-17–producing ThIL-17 cells induce EAE. (A) PLP-primed DLN 
cells cultured with rIL-23 or rIL-12 for 10 d, labeled with CFSE (peak MFI   
4,654) and transferred (5   106 cells/mouse) into recipient WT SJL mice. 
Cells were tracked at day 3 after immunization, with further gating on 
splenic CFSE  CD4  cells to determine IFN-  and IL-17 production by 
intracellular staining. (B) PLP-primed DLN cells cultured with either rIL-23 
(squares) or rIL-12 (triangles) for 10 d, and transferred into WT SJL mice as 
either purified CD4  cells (3   106 cells/mouse; n   10/group; top), or as 
total DLN cells (7   106 cells/mouse; n   3/group; bottom), with mean EAE 
scores recorded. (C) Mean EAE scores of WT recipient mice (n   5/group) 
passively transferred with graded numbers of ThIL-17 cells: 1.2   106 ThIL-17 
(closed squares), 3   105 ThIL-17 (closed triangles), 1.5   105 ThIL-17 (open 
circles), or 2.0   104 ThIL-17 (open diamonds). Results are summarized from 
two separate experiments. (D) Mean EAE scores of WT recipient mice (n   
5/group) passively transferred with either 5   105 ThIL-17 cells (open squares), 
5   105 Th1 cells (open diamonds), or cotransferred with ThIL-17 plus Th1 
cells (5   105 of each; closed triangles), or ThIL-17 plus sorted IFN-   cells 
(5   105 ThIL-17 plus 2   105 IFN-   cells; closed circles). (C–D) ThIL-17 cell 
numbers are calculated from intracellular cytokine staining analysis, with 
 3-5   106 total DLN cells passively transferred per recipient mouse.JEM VOL. 201, January 17, 2005 237
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and could cross the blood–brain barrier, cells were fluores-
cently labeled before passive transfer. 3 d after transfer, simi-
lar frequencies of labeled cells were detected in the blood,
spleen, and CNS, regardless of whether they were cultured
with IL-23 or IL-12, suggesting both Th1 and ThIL-17 cells
can survive in vivo and traffic to the CNS. In addition, the
transferred cells also remained stable with respect to their
IFN-  or IL-17 production in vivo (Fig. 5 A). Labeled cells
were still detectable 6 d after transfer, but with decreased
mean fluorescence intensity in both groups, indicative of
normal proliferation/division of the cells (unpublished data).
Next, we determined the encephalogenicity of ThIL-17
versus Th1 cell populations. Mice that received either IL-
23–driven ThIL-17 cells (either as purified CD4  T cells or
total DLN containing  3   105 ThIL-17 cells) showed severe
clinical signs of EAE (Fig. 5 B). However, mice that re-
ceived an equivalent number of IL-12–driven Th1 cells
showed no clinical signs of EAE, suggesting that Th1 cells
are less efficient at inducing EAE (Fig. 5 B). When graded
numbers of ThIL-17 were transferred into naive SJL mice,
ThIL-17 cell number directly correlated with disease severity,
regardless of the number of Th1 cells present (Fig. 5 C). To
determine whether the IFN-   cells might negatively regu-
late EAE, next we cotransferred FACS-sorted IFN-   cell
population or Th1 cells with ThIL-17 cells to recipient mice.
Neither IFN-   cells nor Th1 cells could reduce the ThIL-17-
mediated EAE pathology (Fig. 5 D), suggesting that the in-
ability of Th1 cells to induce EAE was not due to regula-
tory components in the IL-12–driven cultures. In addition,
we noted that short-term IL-12–driven cell populations (7 d)
could contain a small number of contaminating IL-17–pro-
ducing cells that can induce mild EAE (Fig. 5 D). These re-
sults demonstrate that IL-17–producing T cells are more
pathogenic than IFN- –producing T cells.
To test whether IL-17 production directly contributes to
EAE severity, PLP-immunized WT SJL mice were treated
with neutralizing antibodies against IL-17 (Fig. 6 A). Anti–
IL-17 treatment resulted in partial protection from EAE,
consistent with a recent paper suggesting that IL-17–defi-
cient mice are resistant to actively induced EAE and CIA
(20), and confirming that the IL-23–IL-17 pathway is im-
portant in inflammatory autoimmune diseases. However, the
observed partial protection indicates that other factors in-
duced by IL-23, including IL-6, IL-17F, and TNF, are also
important in EAE pathogenesis. Indeed, the highly intense
disease induced by passive transfer of ThIL-17 cells (3–5   105
cells/recipient) cannot be blocked by anti–IL-17 antibody
treatment of recipient mice (unpublished data), suggesting
that multiple factors produced by these exceptionally patho-
genic ThIL-17 cells must be neutralized before inhibiting their
actions. In addition, IL-17 may also have a role in the initial
expansion of the ThIL-17 cells as suggested by a recent paper
showing a role for IL-17 during immune priming (21). It
was previously unclear whether the classical Th1-type/IFN-
 –mediated immune response is essential for induction or
maintenance of autoimmune disease. Treatments with IFN- 
lead to disease exacerbation in human MS (22), and trans-
genic mice overexpressing IFN-  in the CNS showed in-
creased oligodendrocyte death leading to demyelinating dis-
eases (23, 24). However, despite the potential toxic effects of
IFN-  in the CNS, mice that lack critical components of the
Th1–IFN-  pathway are highly susceptible to EAE (8–12).
Consistent with this, treatment of PLP-immunized mice
with neutralizing antibodies against IFN-  demonstrated in-
tensified disease leading to  75% mortality (Fig. 6 B), indi-
cating that loss of IFN-  results in disease exacerbation.
DISCUSSION
In this paper, we have identified a pathogenic T cell popula-
tion critical for autoimmune inflammation. This IL-23–medi-
ated immune response is not associated with IFN-  or IL-4
production. IL-23 promotes the development and expansion
of activated CD4  cells that produce IL-17, IL-17F, IL-6, and
TNF upon antigen-specific stimulation. Genetic analysis of
these ThIL-17 cells identified a unique expression pattern of
proinflammatory cytokines and other novel factors. This data,
plus the observation that IFN- –producing cells, are present
in EAE-resistant, IL-23–deficient mice, suggesting that the IL-
23–driven immune response is independent of the IFN- –
Th1 pathway. IL-17 production was undetectable in CD4  T
cells from IL-23–deficient mice (derived from either CNS or
LN), suggesting that IL-23 is essential for the development of
autoantigen-specific T cell production of IL-17. By in vitro
expansion of antigen-primed DLN cells with rIL-23 and pas-
sive transfer studies, we confirm that these IL-23–dependent T
cells are highly pathogenic, and essential for the establishment
of organ-specific inflammation associated with autoimmunity.
In key published EAE passive transfer papers (25, 26),
PLP-primed DLN cells were cultured with rIL-12 for 4 d be-
fore transfer of 20–30   106 cells into recipient mice. Both
Th1 and ThIL-17 cells can be found in antigen-primed DLN
cells immediately after isolation; however, they reduce over
time when cultured with IL-23 or IL-12, respectively. 4 d in
the presence of rIL-12 is not sufficient time for the complete
loss of IL-17 production; therefore, the cells were cultured for
Figure 6. IL-17, not IFN- , contributes to EAE severity. (A) WT SJL 
mice actively immunized with PLP emulsified in CFA, and treated at day 7 
with 200  g anti–IL-17 (closed diamonds) or isotype control (open diamonds), 
n   5/group. (B) WT SJL mice actively immunized with PLP emulsified in 
CFA (using suboptimal immunization strategy to give weaker disease), and 
treated at days 0 and 7 with 200  g anti–IFN-  (closed squares) or iso-
type control (open squares), n   7/group. Plots are representative of three 
similar experiments.IL-23 DRIVES PATHOGENIC T CELLS | Langrish et al. 238
10–14 d with either IL-12 or IL-23 before passive transfer.
Our data indicates that the ThIL-17 cells are far more efficient
than Th1 cells at inducing EAE; as a result, we transferred
 10-fold fewer cells in comparison to the published reports.
A recent paper demonstrated that antigen-primed IFN-  
versus IFN-   cells have differential in vivo survival po-
tentials (27). The IFN-   cells were short-lived and per-
formed immediate effector functions, whereas the IFN-  
cells had increased durability and possessed long-term mem-
ory function. This is consistent with our work demonstrat-
ing the existence of an IFN-   IL-17 –producing T cell
population. In addition, some but not all IFN-   cells could
produce IFN-  at a later stage after strong antigenic stimula-
tion in the presence of IL-12 (27), suggesting a shared a pre-
cursor lineage. In our studies, antigen-primed activated T
cells are responsive to both IL-12 and IL-23. In short-term
in vitro assays, CD62Lhi naive T cells appear to predomi-
nately respond to IL-12 and are biased toward IFN-  pro-
duction after anti-CD3 and anti-CD28 stimulation (Fig. 3,
A and B, and reference 3). In vitro activation of naive T cells
in the presence of IL-23 could induce the generation of a
small population of IL-17–producing T cells; however, dur-
ing this short-term culture, IL-23 was unable to affect resid-
ual IFN-  production. It is likely that during in vivo activa-
tion of naive T cells, an array of cytokines and cellular
interactions are required to optimally induce IL-23 respon-
siveness. For example, naive T cells from autoimmune-
prone DBA-1 mice can be driven to produce IL-17 when
alternatively stimulated via ICOS (28).
The in vivo function of IL-23 remains to be determined,
but appears to be clearly associated with IL-17, IL-17F, IL-6,
and TNF production. IL-17 is an important effector cyto-
kine during inflammation. IL-17–deficient mice are resistant
to CIA and EAE (20), and therapeutic treatment with an IL-
17 antagonist antibody can reverse ongoing CIA (29), con-
sistent with the notion that IL-17 functions during the effec-
tor phase of an inflammatory response. In addition, IL-17
has been found in many human autoimmune diseases, in-
cluding multiple sclerosis (30), rheumatoid arthritis (31), and
psoriasis (32). IL-17–producing T cells have also been iden-
tified in the synovial fluid of patients with Lyme arthritis
(33), suggesting involvement of IL-17 in infection-induced
immunopathology. IL-17 receptors that bind both IL-17 and
IL-17F are ubiquitously expressed in a broad range of cell
types including myeloid and endothelial cells. Engagement
of IL-17 and/or IL-17F on these cell types promotes expres-
sion of IL-1, IL-6, IL-8, TNF, and ICAM-1, which are all
critical factors that drive inflammation (34).
IL-6 is predominately produced by myeloid cells and is an
important factor promoting inflammatory responses. The pro-
duction of IL-6 by ThIL-17 but not Th1 cells is intriguing and
may explain the hyperencephalogenicity of ThIL-17 cells. IL-6
produced by LPS-activated dendritic cells can turn off regula-
tory T cell (T reg cell) function, allowing effector T cell acti-
vation (35). It is tempting to speculate that in the absence of
microbe-activated dendritic cells, the IL-6–producing ThIL-17
cells may have the potential to directly inhibit the action of T
reg cell function within the target organ during autoimmune
inflammation. The role of TNF in chronic inflammatory dis-
eases is well recognized (36). Interestingly, TNF is produced
by both Th1 and ThIL-17 cells after in vitro stimulation, sug-
gesting that TNF may play a role in both IL-12 and IL-23
linked immune responses. Thus, the cellular mechanism of
action of IL-23 in autoimmunity is the expansion of self-reac-
tive IL-17, IL-17F, TNF, and IL-6–producing T cells. Im-
portantly, this IL-23–mediated immune response has a
different gene expression pattern than IL-12–driven T cell re-
sponses. Understanding the molecular basis for the differential
gene expression pattern of the IL-23–dependent T cell popu-
lation could provide additional therapeutic targets for the
treatment of inflammatory autoimmune diseases.
MATERIALS AND METHODS
Mice. IL-23p19    (IL-23–deficient mice) and their WT controls were
generated on a mixed B6   129 background using approaches described
previously (1).
SJL/J and IL-12p40–deficient (p40    C57BL/6) mice were obtained
from The Jackson Laboratory. All animal procedures were approved by the
DNAX IACUC committee, in accordance with AAALAC guidelines.
EAE. EAE was induced in female mice at 8–12 wk and clinically assessed as
described previously (1), using 100  g MOG35-55 per mouse for B6   129
and C57BL/6 strains, or 80  g PLP139-151 (PLP) per mouse for SJL strains and
emulsified in CFA. Where required, brain- and spinal cord–infiltrating cells
were isolated from MOG-immunized WT and IL-23p19    mice at day 7
(before EAE onset; reference 1), and cultured with 100  g/ml MOG for 18 h
(plus Golgi-Plug for final 4 h) before intracellular cytokine staining.
Intracellular cytokine flow cytometry.  Cells were surface stained with
anti–CD4-FITC in the presence of Fc blocking antibodies. Cells were washed,
fixed, permeabilized with Cytofix/Cytoperm buffer and intracellular stained
with antibodies against IFN- /TNF/IL-17/IL-6/IL-4, and analyzed with a
FACScalibur flow cytometer. For DLN and naive T cell intracellular cyto-
kine staining, samples were restimulated with 50 ng/ml PMA and 500 ng/
ml ionomycin (Sigma-Aldrich) in the presence of Golgi-plug for 4 h, before
surface staining with combinations of antibodies against CD4/CD45RB/
CD62L/CD44 and intracellular cytokine staining with combinations of an-
tibodies against IFN- /IL-17/TNF/IL-4. All antibodies and staining buff-
ers were purchased from BD Biosciences.
DLN cultures and passive transfer. Inguinal, axillary, and branchial LNs
were harvested from SJL mice 9 d after antigen immunization. DLN cells
were cultured in complete RPMI 1640 media containing 10% FCS, supple-
mented with Pen-Strep, L-glutamine, Hepes, sodium pyruvate, and 2-ME,
in the presence of 20  g/ml PLP139-151 for an initial 5 d, plus addition of ei-
ther 10 ng/ml rIL-12 or 10 ng/ml rIL-23. Media was replaced on days 5
and 8 and supplemented with 2 ng/ml IL-2 (BD Biosciences), plus rIL-23
or rIL-12. At day 5, cells initially cultured with IL-12 were rested without
IL-12 for 3 d to prevent excessive apoptosis. As required, day 10 cultured
DLN cells were positively selected and enriched using CD4  microbeads
(Miltenyi Biotec) with  95% purity. For passive transfer, SJL DLN cells
(either total DLN or CD4  MACS enriched) were harvested, washed in
RPMI 1640, and injected i.v. into naive WT female SJL mice (see Fig. 5 for
culture conditions and cell number in each experiment). The frequency of
ThIL-17 and Th1 cells was calculated by intracellular flow cytometry per-
formed in parallel for each sample. For IL-12p40    cultures, DLN cells
were harvested from p40    mice at day 9 after MOG immunization and
cultured with 100  g/ml MOG35-55 peptide plus 10 ng/ml rIL-12 or 10
ng/ml rIL-23 for 5 d before analysis.JEM VOL. 201, January 17, 2005 239
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Naive T cell cultures and adoptive transfer. DLN and spleen cells were
isolated from naive DO11.10 Tg   Rag    mice, and CD4  cells were pu-
rified by MACS. For culture, 106 naive CD4  spleen cells/ml were acti-
vated for 3 d with 10  g/ml of plate-bound anti-CD3 and 1  g/ml anti-
CD28 with 10 ng/ml rIL-12 or 10 ng/ml rIL-23. Cultured cells were
rested for 4 d before restimulation with PMA/ionomycin in the presence of
Golgi-plug for intracellular cytokine staining on day 7. For adoptive trans-
fer, pooled naive CD4  MACS-purified spleen and LN cells from
DO11.10 Tg    Rag    mice were pooled and injected into recipient
BALB/c mice, with each mouse receiving  5   106 CD4  KJ1-26  cells.
Recipient mice were immunized with 20  g OVA323-339 peptide emulsified
in CFA on day 2, and the DLN cells were harvested on day 6 and immedi-
ately analyzed for intracellular cytokine staining after PMA/ionomycin re-
stimulation. Where required, cells were surface stained with combinations
of fluorescently labeled antibodies KJ1-26, CD4, CD62L, and CD44.
Gene expression analysis.  RNA was extracted from DLN cells isolated
from naive SJL non–PLP-primed control mice (unprimed), and as total
DLN or CD4  MACS-enriched cells from PLP-immunized mice. These
cells were either not cultured (ex vivo) or cultured with rIL-23 or rIL-12
for 10 d. All samples were activated with 50 ng/ml PMA and 500 ng/ml
ionomycin (Sigma-Aldrich) for 4 h before cDNA preparation. mRNA ex-
pression was quantitated by real-time PCR as described previously (2).
Fluorescent dye staining and tracking. SJL DLN cells cultured for 10 d
with either IL-23 or IL-12 were labeled with CFSE (Molecular Probes),
transferred i.v. into naive recipient mice (5   106 total cells/mouse). At day
3 after transfer, spleens were removed and homogenized, red blood cells
were lysed, and mononuclear cells were surface stained with anti–CD4-
APC and intracellular stained with anti–IL-17 or anti–IFN-  as described
before. Blood was collected and lysed (RBC lysis buffer; Sigma-Aldrich),
and mononuclear cells from brains and spinal cord tissue were prepared as
described previously (1) and surface stained with anti–CD4-APC.
Sorting of IFN-   and IFN-  DLN cells. IFN-   and IFN-   cells
were sorted from PLP-primed SJL DLN cells cultured with rIL-12 for 10 d,
after 3 h stimulation with anti-CD3/anti-CD28, using anti-CD45 anti–
IFN-  bispecific antibody-capture matrix kit (Miltenyi Biotec) as described
previously (27).
Antibody treatment of EAE.  WT SJL mice were treated with 200  g
i.p anti–IL-17 (clone 18H10, rat IgG1), or treated with anti–IFN-  (clone
XMG1.2, rat IgG1) or relevant isotype controls, immunized with PLP139-151
as described before. Both neutralizing antibodies were generated at DNAX
(with  4 EU/mg of mAb); however, they are also commercially available
from BD Biosciences, Southern Biotechnology Associates, Inc., and Up-
state Biotechnology.
Online supplemental material. Fig. S1 demonstrates that both ThIL-17
and Th1 cells produce TNF, but not IL-4, and are phenotypically charac-
terized as CD4 CD44hiCD62Llo indicative of activated T cells. Online sup-
plemental material is available at http://www.jem.org/cgi/content/full/
jem.20041257/DC1.
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